Vanda Pharmaceuticals (VNDA) stock: insider trades, news & valuation
Heavy sellingShare price and insider trades
Vanda Pharmaceuticals insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 6 sold $2.8M of VNDA stock on the open market.
Get emailed when insiders cluster-buy stocks like VNDA
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
VNDA insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | — | 0 |
| Q2 2026 | — | 0 | — | 0 |
| Q1 2026 | — | 0 | $2.8M | 6 |
Valuation, profit and volume
Summary
Over the past 12 months, 0 Vanda Pharmaceuticals Inc. insiders reported open-market purchases totaling $0, while 6 insiders reported sales totaling $2.8M. 0 of 6 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Mar 4SEC | Mihael Hristos PolymeropoulosCEO, President | Sell | 156,2352,704,496 held (−5%) | $8.17 | $1.3M | -44.1% | — |
| Mar 4SEC | Kevin Patrick MoranCFO | Sell | 42,442411,380 held (−9%) | $8.27 | $351K | -44.7% | — |
| Mar 4SEC | Timothy WilliamsGeneral Counsel | Sell | 42,434377,450 held (−10%) | $8.27 | $351K | -44.7% | — |
| Mar 4SEC | Gunther BirznieksSvp, Business Development | Sell | 42,431494,197 held (−8%) | $8.27 | $351K | -44.7% | — |
| Mar 4SEC | Joakim WijkstromSvp, Chief Marketing Officer | Sell | 30,800333,469 held (−8%) | $8.27 | $255K | -44.7% | — |
| Feb 24SEC | Tage HonoreDirector | Sell | 30,00093,469 held (−24%) | $8.03 | $241K | -43.1% | — |
Insiders at Vanda Pharmaceuticals Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Mihael Hristos PolymeropoulosCEO, President | — | $1.3M | Mar 4, 2026 | — |
| Kevin Patrick MoranCFO | — | $351K | Mar 4, 2026 | — |
| Timothy WilliamsGeneral Counsel | — | $351K | Mar 4, 2026 | — |
| Gunther BirznieksSvp, Business Development | — | $351K | Mar 4, 2026 | — |
| Joakim WijkstromSvp, Chief Marketing Officer | — | $255K | Mar 4, 2026 | — |
| Tage HonoreDirector | — | $241K | Feb 24, 2026 | — |
VNDA stock: common questions
Are Vanda Pharmaceuticals Inc. insiders buying VNDA stock?
In the past 12 months, 0 insiders reported open-market purchases of VNDA worth $0.
Are Vanda Pharmaceuticals Inc. insiders selling VNDA stock?
6 insiders reported sales worth $2.8M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is VNDA's 52-week range?
Over the past year VNDA has traded between $4.32 and $9.56. It last closed at $4.57 on Oct 9, 2026.